Zinc may hold key to fighting liver disease

June 1, 2017, Westmead Institute for Medical Research
Associate Professor Golo Ahlenstiel and Doctor Scott Read from the Westmead Institue in Sydney have shown that serum zinc may benefit liver disease in a way we never expected. Credit: The Westmead Institute for Medical Research

New research from the Westmead Institute's Storr Liver Centre in collaboration with the Centre for Virus Research and Kirby Institute has shown that serum zinc may benefit liver disease in a way we never expected.

The study, led by Dr Scott Read and Associate Professor Golo Ahlenstiel, demonstrated that zinc naturally inhibits the inflammatory and antiviral effects of interferon lambda 3 (IFN-λ3), a protein strongly associated with tissue damage in .

Lead author of the study, Dr Read, said the study provides the first evidence that zinc can act as a potent and specific inhibitor of IFN-λ3 in the context of viral infections such as hepatitis C and influenza.

"We have demonstrated that zinc inhibits numerous facets of the liver's immune response to viruses that may be mediated by IFN-λ3."

"Zinc interferes with IFN-λ3 binding to the interferon lambda receptor, which results in decreased antiviral activity and increased viral replication both in vitro and in vivo.

"Interestingly, zinc also blocks the inflammatory activity of IFN-λ3, which has been strongly linked to accelerated progression to liver cirrhosis in viral and non-viral .

"Our data suggests that serum zinc levels in patients with chronic hepatitis C are genetically predetermined by the IFN-λ3 polymorphism, confirming the inhibitory role of zinc in vivo.

"The data highlights the potential for to be used as a simple and effective treatment against acute and chronic inflammation in the ," Dr Read concluded.

Associate Professor Ahlenstiel and his team are now working towards a therapeutic intervention for IFN-λ3-mediated chronic .

This research was published online in Nature Communications.

Explore further: Zinc acetate lozenges may increase the recovery rate from the common cold by threefold

More information: Scott A. Read et al, Zinc is a potent and specific inhibitor of IFN-λ3 signalling, Nature Communications (2017). DOI: 10.1038/ncomms15245

Related Stories

Zinc acetate lozenges may increase the recovery rate from the common cold by threefold

May 11, 2017
According to a meta-analysis of three randomized controlled trials zinc acetate lozenges may increase the rate of recovery from the common cold three fold. On the fifth day, 70% of the zinc lozenge patients had recovered ...

Common cold duration is shortened similarly by zinc acetate and zinc gluconate lozenges

May 3, 2017
There is no significant difference between zinc acetate lozenges and zinc gluconate lozenges regarding their efficacy in shortening the duration of common colds according to a meta-analysis published in Journal of the Royal ...

Zinc supply affects cardiac health

April 18, 2017
In addition to essential metabolic functions, the level of zinc in the body also affects the heart muscle. When oxidative stress occurs, it may be due to a shortage of zinc, which can be determined by examining the heart ...

A link between zinc transport and diabetes

September 24, 2013
Individuals with a mutation in the gene encoding a zinc transporter, SLC30A8 have an elevated risk of developing type 2 diabetes. Insulin granules that are released from pancreatic β cells contain high levels of zinc; however, ...

Zinc levels may predict worse outcomes with alopecia

July 10, 2015
(HealthDay)—Lower serum zinc levels are associated with worse outcomes in patients with alopecia areata, according to a study published online July 3 in the International Journal of Dermatology.

Eight ways zinc affects the human body

July 21, 2014
Researchers identified zinc as one of the most important essential trace metals in human nutrition and lifestyle in a new review article in Comprehensive Reviews in Food Science and Food Safety, published by the Institute ...

Recommended for you

Study reveals new therapeutic target for slowing the spread of flu virus

June 22, 2018
Influenza A (flu A) hijacks host proteins for viral RNA splicing and blocking these interactions caused replication of the virus to slow, according to new research published in Nature Communications by Kristin W. Lynch, Ph.D., ...

First ancient syphilis genomes decoded

June 21, 2018
An international research team, including scientists from the Max Planck Institute for the Science of Human History, the University of Tübingen, the National School of Anthropology and History in Mexico City, and the University ...

Rhesus macaque model offers route to study Zika brain pathology

June 21, 2018
Rhesus macaque monkeys infected in utero with Zika virus develop similar brain pathology to human infants, according to a report by researchers at the California National Primate Research Center and School of Veterinary Medicine ...

California Aedes mosquitoes capable of spreading Zika

June 21, 2018
Over the last five years, Zika virus has emerged as a significant global human health threat following outbreaks in South and Central America. Now, researchers reporting in PLOS Neglected Tropical Diseases have shown that ...

Breakthrough treatment for crippling jaw disease created

June 20, 2018
A first-ever tissue implant to safely treat a common jaw defect, known as temporomandibular joint dysfunction, has been successfully tested by UCI-led researchers in a large animal model, according to new findings.

Cell-free DNA profiling informative way to monitor urinary tract infections

June 20, 2018
Using shotgun DNA sequencing, Cornell University researchers have demonstrated a new method for monitoring urinary tract infections (UTIs) that surpasses traditional methods in providing valuable information about the dynamics ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.